Transcription
World TB Day 2016Global is Local: Opportunities andChallenges for TB Elimination inNew York CityEPIDEMIOLOGYSTONY WOLDHERBERT FUND
AGENDA8:30 – 9:00CO F F E E AND PASTR IE S9:00 – 9:25W E LCO ME AND OVE RVIE W O F THECO N F E R E NC ENeil W. Schluger, MDProfessor of Medicine, EnvironmentalHealth Sciences, and Epidemiology; Chief,Pulmonary, Allergy, and Critical CareMedicine; Columbia University11:00 – 12:00 EN G AG IN G THE PATIEN T AN DCOMMUN ITY IN TB PREVEN TION :LEARN IN G F ROM DRUG - RESISTAN TTB HIV OUTB REAK S IN N EW YORKCITY AN D SOUTH AF RICAFACILITATORWafaa El-Sadr, MD, MPH, MPAUniversity Professor of Epidemiology andMedicine; Mathilde-Krim-amfAR Professorof Global Health; Director, ICAP; ColumbiaUniversityMary T. Bassett, MD, MPHCommissioner, New York City Department ofHealth and Mental HygieneMax O’Donnell, MD, MPHAssistant Professor of Medicine andEpidemiology; Columbia University9:25 – 10:15Gerald H. Friedland, MDProfessor of Medicine and Epidemiology;Yale UniversityNesri Padayatchi, MBChB, MScDeputy Director; Centre for the AIDSProgramme of Research in South Africa(CAPRISA)T H E G LOBAL TB E P IDE MIC 2 0 1 5E. Jane Carter, MDPresident of the International Union AgainstTuberculosis and Lung Disease; AssociateProfessor of Medicine; Director of BrownKenya Program; Brown University WarrenAlpert Medical School12:00 - 12:10 LOUDER THAN TBJoanna BreitsteinSenior Director, Communications;TB Alliance10:15 – 10:45 T H E STAT E O F TB IN NE W YO R K CITY2015Joseph Burzynski, MD, MPHAssistant Commissioner and Director, Bureauof Tuberculosis Control; New York CityDepartment of Health and Mental Hygiene10:45 – 11:00 CO F F E EJennifer Zelnick, MSW, ScDAssociate Professor, Touro College;Graduate School of Social WorkAnne Detjen, MDChildhood TB Specialist,United Nations Children’s Fund (UNICEF)12:10 - 1:20LUN CH AN D OPTION AL CASE- B ASEDB REAKOUT PAN ELSS E S S IO N A:MDR-T BSundari Mase, MD, MPHDivision of Tuberculosis Elimination, NationalCenter for HIV/AIDS, Viral Hepatitis, STD, andTB Prevention; Centers for Disease Controland PreventionFelicia F. Dworkin, MDDeputy Director, Medical Affairs; Bureauof Tuberculosis Control; New York CityDepartment of Health and Mental HygieneBriana Short, MDPostdoctoral Fellow, Pulmonary/Critical Care;Columbia University2
AGENDAS ES S I O N B :TB HIVEric Leibert, MDAssociate Director, Bellevue Chest Service;Director of Bronchoscopy, Bellevue HospitalCenter; Director of Bronchoscopy, TischHospital2:00 - 3:00PATIEN T- CEN TERED CARE IN TB :SETTIN G THE AG EN DAFACILITATORYael Hirsch-Moverman, PhD, MPHAssistant Professor of Epidemiology (inICAP); Columbia UniversityMax O’Donnell, MD, MPHAssistant Professor of Medicine andEpidemiology; Columbia UniversityMike Frick, MScTB/HIV Project Officer,Treatment Action Group (TAG)Ewa Rakowski, MDPostdoctoral Fellow, Pulmonary/Critical Care;New York UniversityS ES S I O N C:EX T R AP U LMON A RY AN D CN STBJoseph Burzynski, MD, MPHAssistant Commissioner Director, Bureauof Tuberculosis Control; New York CityDepartment of Health & Mental HygieneKiran Thakur, MDAssistant Professor of Neurology;Columbia UniversityMarian Loveday, MPhil, PhDSpecialist Scientist, South African MedicalResearch CouncilA. Ross Hill, MDPulmonary & Critical Care Medicine, SUNYDownstate Medical Center at Brooklyn;Medical Director, DOT Program for TB; KingsCounty Hospital CenterJ. Lucian (Luke) Davis, MD, MASAssociate Professor, Department ofEpidemiology of Microbial Diseases; YaleSchool of Public Health; Pulmonary, CriticalCare, and Sleep Medicine Section;Yale School of MedicineNicholas Morris, MDPostdoctoral Fellow, Neurology;Columbia UniversityAudrey Daggan, MDPostdoctoral Fellow, Pulmonary/Critical Care;Columbia UniversityS ES S I O N D:B EH AV I O R A LA N D S OCIA LS CI EN CE / TBCA S EMA N AGE ME N TMarian Loveday, MPhil, PhDSpecialist Scientist; South African MedicalResearch CouncilSCIEN TIF IC CHALLEN G ES:IMPLICATION S OF MYCOB ACTERIALPERSISTEN CE F OR TB PREVEN TIONWilliam R. Jacobs, PhDProfessor of Genetics and Microbiology &Immunology; Albert Einstein College ofMedicineChristine Chuck, MPADirector, Field Operations; Bureau ofTuberculosis Control; New York CityDepartment of Health and Mental HygienePaul Colson, PhD, MSWAssociate Research Scientist, ICAP;Columbia University1:20 - 2:003:00 - 3:303:30 - 4:00CON TROVERSIES IN G LOB AL TB :IMPLICATION S F OR TB ELIMIN ATIONIN N EW YORK CITYNeil W. Schluger, MD4:00WRAP UP AN D FAREWELLCO M M U N ITY-BASE D AP P R OAC HE STO T B O UTBR E AKS: R E SP O NSE INN E W YO R K CITYJeanne Sullivan Meissner, MPHPublic Health Epidemiologist, Bureauof Tuberculosis Control, New York CityDepartment of Health and Mental Hygiene3
4
PARTICIPANTSMARY T. BASSETT, MD, MPHJOANNA BREITSTEINCommissioner, New York CityDepartment of Health and MentalHygieneSenior Director, CommunicationsTB AllianceDr. Bassett was appointed Commissioner of Health of NewYork City in February 2014. Her focus is on ensuring thatevery New York City neighborhood supports the health of itsresidents, with the goal of closing gaps in population healthacross this diverse city. Originally from New York City, Dr.Bassett lived for nearly 20 years in Zimbabwe. Previously, shewas a Program Director for the African Health Initiative andthe Child Well-being Program at the Doris Duke CharitableFoundation. She completed her medical residency at HarlemHospital Center, and has a master’s degree in Public Healthfrom the University of Washington.Ms. Breitstein is the Senior Director, Communications, ofTB Alliance, a not-for-profit organization with the mission ofdiscovering and developing improved TB drugs for all. Shejoined the organization in 2009. In her role, Ms. Breitstein isresponsible for charting the organization’s communicationsstrategy in support of TB Alliance’s mission. She also servesas the point person for the Louder than TB campaign, a coalition of cross-sector partners working to raise awareness andpromote integration, innovation, and investment in TB. Beforejoining TB Alliance, Ms. Breitstein was the Executive Editor ofPharmaceutical Executive, a healthcare magazine. She is alsothe Co-founder and Board Member of The International HUGFoundation, a 501c3 organization with the mission of helpingvulnerable children in Uganda.5
JOSEPH BURZYNSKI, MD, MPHE. JANE CARTER, MDAssistant Commissioner and Director,Bureau of Tuberculosis ControlNew York City Department of Healthand Mental HygienePresident of the International UnionAgainst Tuberculosis and LungDiseaseAssociate Professor of Medicine;Director of Brown Kenya Program;Brown University Warren AlpertMedical SchoolUnder Dr. Burzynski’s guidance, the Bureau of TB Control continues to implement innovative policies and procedures toprevent the spread of TB and to eliminate it as a public healthproblem in NYC. Dr. Burzynski has worked as the Physicianin Charge in many Bureau of TB Control chest centers, mostrecently in Corona, Queens. Since 2000, he has been a coinvestigator in the Tuberculosis Trials Consortium. In his workat the Tuberculosis Trials Consortium, he served for 6 years onthe Core Science Committee.6Dr. Carter’s training is in Pulmonary and Critical Care, butthe emphasis of her clinical practice for the last 25 years hasbeen in tuberculosis. She has worked domestically as theMedical Director of the RI TB Clinic from 1990-2007 and as asenior consultant in the RI clinic until 2013. She served on theAdvisory Committee for the Elimination of TB at CDC, completing that term this year and is a member of the NationalTB Controller’s Association and STOP TB USA. Internationally,Dr. Carter has worked in Kenya for 16 years, presently asthe TB/HIV technical consultant for USAID AMPATH (Eldoret,Kenya) and as the PI of TB Reach (Wave 2- year 1 and 2) whichconcentrates on active community based TB case finding,pediatric contact investigation and expansion of TB GenXpertdiagnostics through western Kenya. She is presently servingon the proposal review committee for TB Reach at WHO,the TB technical committee of the Global Fund Against HIV,TB and Malaria, and the TB Modeling and Analysis consortium. She also serves as a medical consultant at the GlobalTuberculosis Institute at Rutgers, The State University of NewJersey. She is the current president of the International UnionAgainst TB and Lung Disease.
CHRISTINE CHUCK, MPAPAUL COLSON, PhD, MSWDirector of Field OperationsBureau of TB ControlNew York City Department of Healthand Mental HygieneAssociate Research ScientistICAP at ColumbiaMs. Chuck is responsible for Citywide management of allreported TB cases from diagnosis to treatment completion.She provides oversight to the City’s sizable directly observedtherapy (DOT) program, contact investigation, and casemanagement of suspected and confirmed TB cases. Sheheaded a team of TB experts in the development, pilotingand subsequent full-scale implementation of synchronous(live-streaming) and asynchronous (recorded) video directlyobserved therapy (VDOT) in NYC. She is focused on increasing the use of technology in TB control as a mechanism tooptimize delivery of care to patients. Ms. Chuck holds aMaster’s degree in Public Administration from Baruch Collegeand has worked in public health for over 25 years in a varietyof capacities. She has extensive knowledge of TB controland has hosted health care partners from the national andinternational arena on best practices in TB control.Dr. Colson holds Masters and Doctoral degrees in social workfrom the School of Social Service Administration, Universityof Chicago. He has an overarching interest in the deliveryof health and mental health services for disadvantagedpopulations, including behavioral and systemic issues whichimpact service use. From 2000 to 2012, he served as ProgramDirector for the Charles P. Felton National Tuberculosis Center,a CDC-funded “model tuberculosis center” under the direction of Dr. Wafaa El-Sadr. He has conducted several studiesof knowledge and attitudes toward tuberculosis and LatentTB Infection (LTBI) with the foreign-born, African-Americans,and other population groups. Dr. Colson has served as aco-investigator in two NIH-funded RCTs of peer interventionsto increase adherence to LTBI treatment. Through the CDCfunded TB Epidemiologic Studies Consortium, he workedwith Dr. Yael Hirsch-Moverman to conduct prospective andretrospective studies of acceptance and completion of LTBItreatment.7
AUDREY DAGGAN, MDJ. LUCIAN (LUKE) DAVIS, MD, MASPostdoctoral Fellow,Pulmonary/Critical CareColumbia UniversityAssociate Professor, Department ofEpidemiology of Microbial Diseases,Yale School of Public HealthPulmonary, Critical Care, and SleepMedicine Section, Yale School ofMedicineDr. Daggan earned her MD from Tuft’s University School ofMedicine and completed a residency in internal medicine atthe University of Pennsylvania. She is now a postdoctoralfellow in pulmonary and critical care medicine at ColumbiaUniversity.8Dr. Davis is a pulmonary/critical care physician and epidemiologist at the Yale School of Public Health and the Yale Schoolof Medicine. His research focuses on improving tuberculosis(TB) diagnosis in resource-constrained settings. One lineof research employs “systems epidemiology” – combiningclinical epidemiology and systems biology - to identify novelbiomarkers for active TB diagnosis and treatment monitoring.The second line of research employs implementation scienceto design, introduce, and evaluate mobile health interventions to improve clinic and community-based active TB casefinding. Two overriding objectives of the research are todevelop approaches to TB evaluation that are more patientcentered, and to provide training opportunities for juniorinvestigators at international sites.
ANNE DETJEN, MDFELICIA DWORKIN, MD, FCCPChildhood TB SpecialistUnited Nations Children’s Fund(UNICEF)Deputy Director, Medical AffairsBureau of Tuberculosis ControlNew York City Department of Healthand Mental HygieneDr. Detjen joined UNICEF in 2015 to develop strategy andprogramming for childhood TB as integrated part of UNICEFswork around strengthening community and primary healthsystems, and to increase advocacy and awareness forchildhood TB in the broader maternal and child health space.Prior to this she was a consultant in child lung health for theInternational Union Against Tuberculosis and Lung Disease(The Union). Trained in pediatrics in Germany she has workedin childhood TB for over ten years. She spent two years at theDesmond Tutu TB Centre in Cape Town, South Africa focusingon TB diagnosis in children. With the Union, she led the development of the childhood TB learning portal and childhoodTB online training course (https://childhoodtb.theunion.org/),and worked with The Union and NTP Uganda to implementroutine TB contact screening at the community level. Sheis a member of the core team of the WHO Childhood TBsubgroup.Dr. Dworkin has been with the New York City Department ofHealth and Mental Hygiene, Bureau of Tuberculosis Controlfor the past 16 years, having held several clinic and fieldmedical positions. Since 2004, she has been the DeputyDirector of Medical Affairs, assisting in the development ofTB policies and procedures, providing direct patient care, aswell as being an expert medical consultation on all aspectsof tuberculosis. She is also responsible for the oversight oftreatment and management for all drug resistant cases inNYC, including MDR and XDR TB patients. Additionally, shecoordinates the bureau’s relationship with the public healthlaboratories in NYC and NYS, as well as other laboratories,and has an extensive understanding in aspects of molecular& drug susceptibility testing for TB as well as supervisesfalse positive investigation. She has extensive knowledgeand experience in management & therapy related issuessurrounding difficult TB cases.9
WAFAA EL-SADR, MD, MPH, MPAMIKE WATSON FRICK, MScUniversity Professor of Epidemiologyand MedicineMathilde-Krim-amfAR Professor ofGlobal HealthDirector, ICAP at Columbia UniversityTreatment Action GroupDr. El-Sadr leads ICAP at Columbia University and the GlobalHealth Initiative at the Mailman School of Public Health. Dr.El-Sadr’s interests include: HIV/ AIDS, tuberculosis maternal/child health, capacity building and health systems strengthening. Her work bridges interest and commitment to localand global public health challenges and an appreciationof the breadth of issues needed to transform the health ofpopulations. She has extensive research experience andleads the NIH-funded HIV Prevention Trials Network. ThroughICAP, the center she established more than a decade ago,she has led the efforts that enabled the establishment oflarge-scale programs in 20 countries in Africa and Asia thatlink research, education, training and practice. She receivedher medical degree from Cairo University in Egypt, a mastersin public health from Columbia School of Public Health (inEpidemiology) and a masters in public administration fromHarvard University’s Kennedy School of Government. Herscholarly work has appeared in leading scientific journals.She was named a MacArthur Fellow in 2008 and a member ofthe National Academy of Medicine in 2009.10Mike Frick is the TB/HIV project officer at Treatment ActionGroup, an independent AIDS research and policy think tankfighting for better treatment, a vaccine and a cure for AIDSand its two major co-infections, tuberculosis and hepatitis C.Mike holds a bachelor’s degree in international studies andChinese from Kenyon College and a master of science degreein global health and population from the Harvard School ofPublic Health.
GERALD H. FRIEDLAND, MDROSS HILL, MD, CMProfessor of Medicine andEpidemiologyYale UniversityPulmonary & Critical Care Medicine,SUNY Downstate Medical Center atBrooklynMedical Director, DOT Program for TBKings County Hospital CenterDr. Friedland has worked in clinical and clinical and epidemiologic research and care of people living with HIV, AIDSand TB since 1981. During the past decade this has includedwork in KwaZuluNatal, South Africa addressing issues in HIV/TB integration and MDR and XDR TB epidemiology, care andtreatment. He is Professor of Medicine and Epidemiologyand Public Health at the Yale School of Medicine andAdjunct Professor at the Mailman School of Public Health atColumbia.A native of Maine, Dr. Hill received his university and medicaleducation at McGill University, Montréal, Québec. Aftersubspecialty training in Respiratory Medicine at McGill, hewas a Parker B. Francis Fellow at the University of Virginia. In1984 Dr. Hill joined the faculty of SUNY Downstate MedicalCenter at Brooklyn, where he has pursued a varied menuof activities in patient care, medical education, and clinical research. His teaching and administrative roles haveincluded program director, Fellowship in Pulmonary &Critical Care Medicine (2003– ); director, Respiratory Blockfor 2nd-year medical students (2003-13); design team forthe Cardiovascular-Respiratory-Renal Unit in the College ofMedicine’s renewed curriculum (2013– ); and member, DMCIRB (1992– ). Since 1984 Dr. Hill’s clinical practice has beenbased at Kings County Hospital Center, Brooklyn’s largesthealthcare facility, where he has served as medical wardand MICU attending, consultant in respiratory medicine, anddirector of the Adult Chest Clinic (1992-2010). His involvementin tuberculosis care has proved particularly rewarding. Heinitiated KCHC’s Directly Observed Therapy Program for TB in1993 and continues as its medical director.11
YAEL HIRSCH-MOVERMAN, PhD,MS, MPHAssistant Professor of Epidemiology(in ICAP)Columbia UniversityDr. Hirsch-Moverman has an MS in Operations Researchfrom Columbia University’s School of Engineering andApplied Science and an MPH and PhD in epidemiology fromColumbia’s MSPH. She has vast experience in conductingepidemiologic and implementation science research, specifically in designing, conducting, and analyzing interventionsto improve adherence and retention in TB/HIV programs.She is co-investigator of two implementation science clusterrandomized trials that evaluate interventions to improve TB/HIV adherence in Ethiopia and Lesotho. She was recentlyawarded an NIH Mentored Research Scientist DevelopmentAward to evaluate a community-based intervention for theprevention of childhood TB in Lesotho.12WILLIAM R. JACOBS, JR., PhDProfessor of Genetics andMicrobiology & ImmunologyHoward Hughes Medical InstituteInvestigatorAlbert Einstein College of MedicineDr. Jacobs is pioneering the use of molecular genetics tocontrol tuberculosis (TB), identifying the genes that makeMycobacterium tuberculosis virulent, identifying new drugtargets and engineering weakened strains that can be usedas live vaccines. He was the first scientist to introduceforeign DNA into MTB, a technique now regularly usedby TB investigators around the world. Since then he hasdiscovered new ways of killing MTB that could also lead to atherapy to prevent drug-resistant TB strains from developing.He also devised an onsite lab test that not only can quicklydiagnose TB but can also distinguish treatable TB strainsfrom those that are drug resistant—a process that ordinarilytakes months. Dr. Jacobs also assisted in a groundbreakingpartnership between HHMI and the University of KwaZuluNatal in South Africa; which has established an internationalresearch center that will contribute to the worldwide effort tocontrol the TB-HIV co-epidemic and train a new generation ofscientists in Africa. Dr. Jacobs, in collaboration with Dr. BetsyHerold at Einstein, has recently developed a promising vaccine candidate against Herpes viruses. He believes his workon Herpes will hold the key to finally developing an effectivevaccine for TB and other infectious diseases.
ERIC LEIBERT, MDMARIAN LOVEDAY, MPhil, PhDAssociate Director, Bellevue ChestServiceDirector of Bronchoscopy, BellevueHospital CenterDirector of Bronchoscopy,
FACILITATOR Jennifer Zelnick, MSW, ScD Associate Professor, Touro College; Graduate School of Social Work Wafaa El-Sadr, MD, MPH, MPA University Professor of Epidemiology and . Master’s degree in Public Administration from Baruch College and has worked in public health for over 2
